Review



anti timp 1  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems anti timp 1
    Anti Timp 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti timp 1/product/R&D Systems
    Average 96 stars, based on 52 article reviews
    anti timp 1 - by Bioz Stars, 2026-03
    96/100 stars

    Images



    Similar Products

    96
    R&D Systems anti timp 1
    Anti Timp 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti timp 1/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    anti timp 1 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    93
    Proteintech mouse anti timp4
    Mouse Anti Timp4, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti timp4/product/Proteintech
    Average 93 stars, based on 1 article reviews
    mouse anti timp4 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    99
    OriGene anti mouse monoclonal antibody against timp 1
    Anti Mouse Monoclonal Antibody Against Timp 1, supplied by OriGene, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse monoclonal antibody against timp 1/product/OriGene
    Average 99 stars, based on 1 article reviews
    anti mouse monoclonal antibody against timp 1 - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology mouse monoclonal antibody
    Mouse Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal antibody/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    mouse monoclonal antibody - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology mouse anti timp1
    Mouse Anti Timp1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti timp1/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    mouse anti timp1 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    R&D Systems anti timp1 antibody af980
    Fig. 1. TIMP-1fl/fl knockout mice develop a severe EAE phenotype that is immunologically independent. (A) Schematic of design of development of the flox-targeted sites that enabled cell and tissue-specific deletion of <t>TIMP-1</t> in GFAP-Cre-TIMP-1fl/fl mice. (B) Immunocytochemical validation of CRE expression in astrocytes from GFAP-Cre:TIMP-1fl/fl mice, and (C) physiological validation of TIMP-1 mRNA expression in primary astrocytes and absence of TIMP-1 mRNA expression in astrocyte cultures from GFAP-Cre:TIMP-1fl/fl mice (n = 8 per treatment; ANOVA; ****P < 0.0001; where *P < 0.01; ***P < 0.002). (D) Validation of absent TIMP-1 protein expression in primary astrocyte cultures from GFAP-Cre:Timp1fl/f mice (n = 3 biological replicates). (E) Clinical EAE in MOG35-55-treated C57Bl/6 WT and GFAP-Cre:TIMP-1fl/fl mice over 52 d time course (n = 13 to 17/treatment and genotype; 2-way ANOVA, P < 0.0001, where post-hoc multiple-comparisons identified significance at *P < 0.05 and **P < 0.01, as indicated). (F and G) Flow cytometry analysis of overall CD4+/IFNγ+ T cells from spinal cords of Wt and GFAP-Cre:TIMP- 1fl/fl mice at peak clinical EAE illness (day 18; n = 3 per genotype and treatment), including (H) analysis of CD4+/IFNγ+ T cells (t test, unpaired t test, P < 0.20).
    Anti Timp1 Antibody Af980, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti timp1 antibody af980/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    anti timp1 antibody af980 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    R&D Systems timp 1
    Fig. 1. TIMP-1fl/fl knockout mice develop a severe EAE phenotype that is immunologically independent. (A) Schematic of design of development of the flox-targeted sites that enabled cell and tissue-specific deletion of <t>TIMP-1</t> in GFAP-Cre-TIMP-1fl/fl mice. (B) Immunocytochemical validation of CRE expression in astrocytes from GFAP-Cre:TIMP-1fl/fl mice, and (C) physiological validation of TIMP-1 mRNA expression in primary astrocytes and absence of TIMP-1 mRNA expression in astrocyte cultures from GFAP-Cre:TIMP-1fl/fl mice (n = 8 per treatment; ANOVA; ****P < 0.0001; where *P < 0.01; ***P < 0.002). (D) Validation of absent TIMP-1 protein expression in primary astrocyte cultures from GFAP-Cre:Timp1fl/f mice (n = 3 biological replicates). (E) Clinical EAE in MOG35-55-treated C57Bl/6 WT and GFAP-Cre:TIMP-1fl/fl mice over 52 d time course (n = 13 to 17/treatment and genotype; 2-way ANOVA, P < 0.0001, where post-hoc multiple-comparisons identified significance at *P < 0.05 and **P < 0.01, as indicated). (F and G) Flow cytometry analysis of overall CD4+/IFNγ+ T cells from spinal cords of Wt and GFAP-Cre:TIMP- 1fl/fl mice at peak clinical EAE illness (day 18; n = 3 per genotype and treatment), including (H) analysis of CD4+/IFNγ+ T cells (t test, unpaired t test, P < 0.20).
    Timp 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/timp 1/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    timp 1 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    93
    R&D Systems prosaposin
    Conditioned media from G17-stimulated melanoma cells exhibit upregulation of MMP-2 and downregulation of TIMP-3 expression. Representative demonstration of the confirmation of proteomic data using Western blot analysis, with <t>prosaposin</t> serving as a benchmark for gastrin responsiveness ( A ). Mean and standard deviation (±SD) of the densitometric analysis results from three independent experiments ( B ). Statistical difference (* p < 0.05) between treated and untreated control groups (considered as 100%) are indicated as follows: prosaposin, TIMP-3 and TIMP-1 levels in G361 cells and MMP2 expressions in the SK-MEL-2 cell line.
    Prosaposin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prosaposin/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    prosaposin - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 1. TIMP-1fl/fl knockout mice develop a severe EAE phenotype that is immunologically independent. (A) Schematic of design of development of the flox-targeted sites that enabled cell and tissue-specific deletion of TIMP-1 in GFAP-Cre-TIMP-1fl/fl mice. (B) Immunocytochemical validation of CRE expression in astrocytes from GFAP-Cre:TIMP-1fl/fl mice, and (C) physiological validation of TIMP-1 mRNA expression in primary astrocytes and absence of TIMP-1 mRNA expression in astrocyte cultures from GFAP-Cre:TIMP-1fl/fl mice (n = 8 per treatment; ANOVA; ****P < 0.0001; where *P < 0.01; ***P < 0.002). (D) Validation of absent TIMP-1 protein expression in primary astrocyte cultures from GFAP-Cre:Timp1fl/f mice (n = 3 biological replicates). (E) Clinical EAE in MOG35-55-treated C57Bl/6 WT and GFAP-Cre:TIMP-1fl/fl mice over 52 d time course (n = 13 to 17/treatment and genotype; 2-way ANOVA, P < 0.0001, where post-hoc multiple-comparisons identified significance at *P < 0.05 and **P < 0.01, as indicated). (F and G) Flow cytometry analysis of overall CD4+/IFNγ+ T cells from spinal cords of Wt and GFAP-Cre:TIMP- 1fl/fl mice at peak clinical EAE illness (day 18; n = 3 per genotype and treatment), including (H) analysis of CD4+/IFNγ+ T cells (t test, unpaired t test, P < 0.20).

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses.

    doi: 10.1073/pnas.2306816121

    Figure Lengend Snippet: Fig. 1. TIMP-1fl/fl knockout mice develop a severe EAE phenotype that is immunologically independent. (A) Schematic of design of development of the flox-targeted sites that enabled cell and tissue-specific deletion of TIMP-1 in GFAP-Cre-TIMP-1fl/fl mice. (B) Immunocytochemical validation of CRE expression in astrocytes from GFAP-Cre:TIMP-1fl/fl mice, and (C) physiological validation of TIMP-1 mRNA expression in primary astrocytes and absence of TIMP-1 mRNA expression in astrocyte cultures from GFAP-Cre:TIMP-1fl/fl mice (n = 8 per treatment; ANOVA; ****P < 0.0001; where *P < 0.01; ***P < 0.002). (D) Validation of absent TIMP-1 protein expression in primary astrocyte cultures from GFAP-Cre:Timp1fl/f mice (n = 3 biological replicates). (E) Clinical EAE in MOG35-55-treated C57Bl/6 WT and GFAP-Cre:TIMP-1fl/fl mice over 52 d time course (n = 13 to 17/treatment and genotype; 2-way ANOVA, P < 0.0001, where post-hoc multiple-comparisons identified significance at *P < 0.05 and **P < 0.01, as indicated). (F and G) Flow cytometry analysis of overall CD4+/IFNγ+ T cells from spinal cords of Wt and GFAP-Cre:TIMP- 1fl/fl mice at peak clinical EAE illness (day 18; n = 3 per genotype and treatment), including (H) analysis of CD4+/IFNγ+ T cells (t test, unpaired t test, P < 0.20).

    Article Snippet: Anti- Fibronectin antibody (Biotin) (ab6584) (Abcam; rabbit, 1:5,000), Anti- Fibronectin antibody (ab23750) (Abcam; rabbit, 1:100- immunodepletion), Anti- Fibronectin antibody (ab2033) (Abcam; rabbit, 1:200), Anti- Timp1 antibody (AF980) (R&D Systems; goat, 1:125), Anti- MBP antibody (12) (Millipore; rat monoclonal, 1:500), Mouse anti- A2B5 (Invitrogen, Carlsbad, CA; 3 μg/mL), DAPI (Invitrogen, 1:1,000), Mouse anti- GFAP (Millipore, 1:400), Beta- actin (Sigma Aldrich, St. Louis, MO; mouse, 1:10,000).

    Techniques: Knock-Out, Biomarker Discovery, Expressing, Flow Cytometry

    Fig. 2. Proteomic identification of elevated fibronectin (Fn) in secretome of TIMP-1KO astrocytes. (A and B) Topographic projections rendered using ProteomeLab™ of PF-2D analyses of extracellular proteins in secretome of primary astrocytes from WT (A and C) and TIMP-1KO (B and D) cultures. (C and D) Magnified view of differential peaks of interest identified by ProteomeLab™ which were interrogated by Liquid chromatography–mass spectrometry. (E) Western blot analysis of fibronectin (Fn) protein expression in ACM CM from WT and TIMP-1KO astrocytes. (F) Quantification of Fn from ACM from primary WT and TIMP-1KO astrocyte cultures showed TIMP-1KO astrocyte cultures had elevated Fn protein levels that were reduced with the addition of rmTIMP-1. (G) Analysis of Fn mRNA expression by qPCR demonstrated no TIMP-1 regulation of Fn mRNA expression in primary TIMP-1KO astrocyte cultures. (H) Validation of immunodepletion of Fn from ACM from primary WT and TIMP-1KO astrocyte cultures. (I) Effect of immunodepletion of Fn from ACM on OL differentiation in vitro in TIMP-1KO and Wt (control) treated cultures. Data in F–I were analyzed by ANOVA with either Bonferroni or Fisher’s least significant difference (LSD) post-hoc tests where appropriate *P < 0.05, **P < 0.01 as indicated. n = 3 biological replicates representing 3 to 4 averaged technical replicates/biological replicate.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses.

    doi: 10.1073/pnas.2306816121

    Figure Lengend Snippet: Fig. 2. Proteomic identification of elevated fibronectin (Fn) in secretome of TIMP-1KO astrocytes. (A and B) Topographic projections rendered using ProteomeLab™ of PF-2D analyses of extracellular proteins in secretome of primary astrocytes from WT (A and C) and TIMP-1KO (B and D) cultures. (C and D) Magnified view of differential peaks of interest identified by ProteomeLab™ which were interrogated by Liquid chromatography–mass spectrometry. (E) Western blot analysis of fibronectin (Fn) protein expression in ACM CM from WT and TIMP-1KO astrocytes. (F) Quantification of Fn from ACM from primary WT and TIMP-1KO astrocyte cultures showed TIMP-1KO astrocyte cultures had elevated Fn protein levels that were reduced with the addition of rmTIMP-1. (G) Analysis of Fn mRNA expression by qPCR demonstrated no TIMP-1 regulation of Fn mRNA expression in primary TIMP-1KO astrocyte cultures. (H) Validation of immunodepletion of Fn from ACM from primary WT and TIMP-1KO astrocyte cultures. (I) Effect of immunodepletion of Fn from ACM on OL differentiation in vitro in TIMP-1KO and Wt (control) treated cultures. Data in F–I were analyzed by ANOVA with either Bonferroni or Fisher’s least significant difference (LSD) post-hoc tests where appropriate *P < 0.05, **P < 0.01 as indicated. n = 3 biological replicates representing 3 to 4 averaged technical replicates/biological replicate.

    Article Snippet: Anti- Fibronectin antibody (Biotin) (ab6584) (Abcam; rabbit, 1:5,000), Anti- Fibronectin antibody (ab23750) (Abcam; rabbit, 1:100- immunodepletion), Anti- Fibronectin antibody (ab2033) (Abcam; rabbit, 1:200), Anti- Timp1 antibody (AF980) (R&D Systems; goat, 1:125), Anti- MBP antibody (12) (Millipore; rat monoclonal, 1:500), Mouse anti- A2B5 (Invitrogen, Carlsbad, CA; 3 μg/mL), DAPI (Invitrogen, 1:1,000), Mouse anti- GFAP (Millipore, 1:400), Beta- actin (Sigma Aldrich, St. Louis, MO; mouse, 1:10,000).

    Techniques: Liquid Chromatography, Mass Spectrometry, Western Blot, Expressing, Biomarker Discovery, Immunodepletion, In Vitro, Control

    Fig. 5. Characterization of Fn and TIMP-1 expression in primary human astrocytes and identification of Ana in human MS proteomic databases. (A) Schematic representation of two modes of analysis of human astrocytes using direct ex vivo, (e.g., scRNAseq) which has indicated no expression or no changes in TIMP-1 expression in astrocytes in the MS brain, and, as used in the present study, in vitro cultures from patient donors. (B) Relative FN1, TIMP1 and ratio FN1 to TIMP1 mRNA expression in control human (ctrl) vs. MS astrocytes as analyzed by qRT-PCR. (C) FN, TIMP1, and ratio FN to TIMP1 protein expression in ctrl human vs. MS astrocytes as analyzed by western blot. (D) Expression of Fn protein in ctrl human and MS astrocytes after TIMP-1 treatment (10 ng/mL human rTIMP-1 for 48 h). The dotted line indicates no treatment (untreated), which was set to 1. * indicates significant difference from untreated control (P < 0.05), one sample t test); ** indicates a significant difference between the two groups (P < 0.01, unpaired student t test). Non-demented control (blue shades 3 to 6) and MS (orange shades, 3 to 6) donors are consistently color-coded in B–D. (E) Proteomic analysis reveals Fn and Ana in the CSF of MS patients. “Low” indicates low cytokine levels in the CSF, while “High” indicates high cytokine levels in the CSF. A and B represent technical replicates.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses.

    doi: 10.1073/pnas.2306816121

    Figure Lengend Snippet: Fig. 5. Characterization of Fn and TIMP-1 expression in primary human astrocytes and identification of Ana in human MS proteomic databases. (A) Schematic representation of two modes of analysis of human astrocytes using direct ex vivo, (e.g., scRNAseq) which has indicated no expression or no changes in TIMP-1 expression in astrocytes in the MS brain, and, as used in the present study, in vitro cultures from patient donors. (B) Relative FN1, TIMP1 and ratio FN1 to TIMP1 mRNA expression in control human (ctrl) vs. MS astrocytes as analyzed by qRT-PCR. (C) FN, TIMP1, and ratio FN to TIMP1 protein expression in ctrl human vs. MS astrocytes as analyzed by western blot. (D) Expression of Fn protein in ctrl human and MS astrocytes after TIMP-1 treatment (10 ng/mL human rTIMP-1 for 48 h). The dotted line indicates no treatment (untreated), which was set to 1. * indicates significant difference from untreated control (P < 0.05), one sample t test); ** indicates a significant difference between the two groups (P < 0.01, unpaired student t test). Non-demented control (blue shades 3 to 6) and MS (orange shades, 3 to 6) donors are consistently color-coded in B–D. (E) Proteomic analysis reveals Fn and Ana in the CSF of MS patients. “Low” indicates low cytokine levels in the CSF, while “High” indicates high cytokine levels in the CSF. A and B represent technical replicates.

    Article Snippet: Anti- Fibronectin antibody (Biotin) (ab6584) (Abcam; rabbit, 1:5,000), Anti- Fibronectin antibody (ab23750) (Abcam; rabbit, 1:100- immunodepletion), Anti- Fibronectin antibody (ab2033) (Abcam; rabbit, 1:200), Anti- Timp1 antibody (AF980) (R&D Systems; goat, 1:125), Anti- MBP antibody (12) (Millipore; rat monoclonal, 1:500), Mouse anti- A2B5 (Invitrogen, Carlsbad, CA; 3 μg/mL), DAPI (Invitrogen, 1:1,000), Mouse anti- GFAP (Millipore, 1:400), Beta- actin (Sigma Aldrich, St. Louis, MO; mouse, 1:10,000).

    Techniques: Expressing, Ex Vivo, In Vitro, Control, Quantitative RT-PCR, Western Blot

    Fig. 6. Proposed model for astrocytic TIMP-1 regulation of OPC differentiation by Ana. Astrocytes when stimulated express and release TIMP-1, which under non-disease conditions would limit the production of Ana from fibronectin. In the absence of astrocytic TIMP-1, like which can occur under chronic inflammatory conditions, the elevated production of Ana impairs OPCs’ differentiation while also blocking the ability of FTY720 to promote differentiation. Together, these factors culminate in reduced remyelination of axons contributing to chronic demyelinating plaques in the CNS of MS patients.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses.

    doi: 10.1073/pnas.2306816121

    Figure Lengend Snippet: Fig. 6. Proposed model for astrocytic TIMP-1 regulation of OPC differentiation by Ana. Astrocytes when stimulated express and release TIMP-1, which under non-disease conditions would limit the production of Ana from fibronectin. In the absence of astrocytic TIMP-1, like which can occur under chronic inflammatory conditions, the elevated production of Ana impairs OPCs’ differentiation while also blocking the ability of FTY720 to promote differentiation. Together, these factors culminate in reduced remyelination of axons contributing to chronic demyelinating plaques in the CNS of MS patients.

    Article Snippet: Anti- Fibronectin antibody (Biotin) (ab6584) (Abcam; rabbit, 1:5,000), Anti- Fibronectin antibody (ab23750) (Abcam; rabbit, 1:100- immunodepletion), Anti- Fibronectin antibody (ab2033) (Abcam; rabbit, 1:200), Anti- Timp1 antibody (AF980) (R&D Systems; goat, 1:125), Anti- MBP antibody (12) (Millipore; rat monoclonal, 1:500), Mouse anti- A2B5 (Invitrogen, Carlsbad, CA; 3 μg/mL), DAPI (Invitrogen, 1:1,000), Mouse anti- GFAP (Millipore, 1:400), Beta- actin (Sigma Aldrich, St. Louis, MO; mouse, 1:10,000).

    Techniques: Blocking Assay

    Conditioned media from G17-stimulated melanoma cells exhibit upregulation of MMP-2 and downregulation of TIMP-3 expression. Representative demonstration of the confirmation of proteomic data using Western blot analysis, with prosaposin serving as a benchmark for gastrin responsiveness ( A ). Mean and standard deviation (±SD) of the densitometric analysis results from three independent experiments ( B ). Statistical difference (* p < 0.05) between treated and untreated control groups (considered as 100%) are indicated as follows: prosaposin, TIMP-3 and TIMP-1 levels in G361 cells and MMP2 expressions in the SK-MEL-2 cell line.

    Journal: International Journal of Molecular Sciences

    Article Title: Elevated Serum Gastrin Is Associated with Melanoma Progression: Putative Role in Increased Migration and Invasion of Melanoma Cells

    doi: 10.3390/ijms242316851

    Figure Lengend Snippet: Conditioned media from G17-stimulated melanoma cells exhibit upregulation of MMP-2 and downregulation of TIMP-3 expression. Representative demonstration of the confirmation of proteomic data using Western blot analysis, with prosaposin serving as a benchmark for gastrin responsiveness ( A ). Mean and standard deviation (±SD) of the densitometric analysis results from three independent experiments ( B ). Statistical difference (* p < 0.05) between treated and untreated control groups (considered as 100%) are indicated as follows: prosaposin, TIMP-3 and TIMP-1 levels in G361 cells and MMP2 expressions in the SK-MEL-2 cell line.

    Article Snippet: Antibodies against MMP-2, TIMP-3 (R&D Systems Abingdon, UK; AF902 and MAB973, respectively), TIMP-1, TIMP-2, prosaposin, and MMP-1 (R&D Systems, Abingdon, UK; AF980, AF971, AF8520, and MAB901, respectively) were utilized.

    Techniques: Expressing, Western Blot, Standard Deviation, Control